MaxCyte Revenue Jumps 49% to $10.2 Million, Raises 2026 Outlook
Key Facts
MaxCyte said on November 10 that total revenue reached $10.2 million in the third quarter of 2026, up 49% from the same period a year earlier, according to a company statement published via MFN. The company raised its full-year revenue outlook to at least $34.5 million, excluding the impact of the proposed acquisition of Akron Bio. The update follows an earlier announcement in October that raised the outlook to about $34 million, compared with a previous range of $30 million to $32 million. Chief Executive Maher Masoud said the company expects core business revenue to grow about 15% year over year in the second half of 2026. The company’s shares closed at $1.3 on November 9, according to EL7 data.
Core business revenue was $8.2 million, up 27% year over year, while revenue from the Strategic Licensing Program reached $2.0 million, compared with $0.4 million in the third quarter of 2025. The results split quarterly revenue between the core business and the licensing program, which recorded an increase from the prior period. The new annual outlook includes about $28 million in core business revenue and at least $6.5 million from the Strategic Licensing Program. The company’s annual estimate therefore remains tied to contributions from both activities, with the proposed deal’s impact excluded from the reported figure. The outlook of at least $34.5 million did not include potential revenue from Akron Bio.
Gross profit rose to $8.5 million, with a gross margin of 83%, compared with $5.2 million and a margin of 77% in the third quarter of 2025, according to the company statement. Operating expenses, meanwhile, fell to $14.5 million from $19.4 million a year earlier. The net loss narrowed to $4.8 million, compared with a loss of $12.4 million in the year-earlier period. The figures show simultaneous improvement in gross profit and margin, alongside lower expenses and a narrower net loss. Masoud attributed the quarterly growth exceeding expectations in part to a large customer bringing forward its equipment purchases, which the company had originally expected in the fourth quarter.
Cash, cash equivalents and investments totaled $132.7 million on September 30, 2026, the company said. It projected a balance of between $40.0 million and $45.0 million at year-end, assuming the Akron Bio deal closes and is funded. That cash estimate is conditional on completion of the deal, while its impact remained excluded from the reported annual revenue outlook. The statement in the evidence provided no details on the acquisition’s value or terms, so the outlook cited does not include an estimate of Akron Bio revenue. The comparison between the balance recorded in September and the projected year-end balance remains based on the assumption that the deal closes and is funded.
Looking ahead, Masoud said core business revenue is positioned to grow about 15% year over year in the second half of 2026. He added that Strategic Licensing Program partners have two pivotal trials that could lead to approvals the following year. The company’s schedule listed its third-quarter results call for November 10 at 4:30 p.m. Eastern Time and the Stifel Healthcare Conference on November 11. Against the backdrop of the share move, the stock rose 25% on October 14 after the preliminary results announcement and the increase to the annual outlook. That move was tied to the October announcement, before the final results and the outlook update issued in November.